Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2024-12-17 00:00:00 ET · period of report 2024-12-15 · accession 0001724521-24-000182 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-12-17 | 2024-12-15 | RCUS | ROSEN TERRY J | CEO, Dir | F - Tax | $16.08 | -37.9K | 2.37M | -2% | -$609.1K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-15 | F | D | 37,882 | $16.08 | 2,369,360 | D | — | — | (F1) Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy the applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. (F2) This amount reflects 1,547,062 shares of the Issuer's Common Stock that are no longer beneficial owned by the Reporting Person as a result of him entering into a "domestic relations order", which change in beneficial ownership is exempt from Section 16 pursuant to Rule 16a-12 under the Securities Exchange Act of 1934, as amended. |